Nanocarriers will account for 40% of a $136 billion nanotechnology-enabled
drug delivery market by 2021. We forecast the total market size in 2021 to be
US$136 billion, with a 60/40 split between nanocrystals and nanocarriers
respectively, although developing new targeted delivery mechanisms may allow
more value to be created for companies and entrepreneurs.
Of the 10 nanocarrier technologies studied, liposomes and gold nanocarriers
account for 45% of the total addressable market. Liposomes will offer the
largest addressable market ($15 billion) in 2021 while gold nanocarriers will
see the highest compound annual growth rate (CAGR) - 53.8% - in the next
decade.
Drugs are loaded into nanocarriers (also called nanoshells or nanoparticles,
between 1 and 100 nm), then transported through the body to the target site.
This kind of targeted drug delivery for the treatment of cancers is one of the
most anticipated and discussed benefits of nanotechnology-enabled medicine as
it offers a level of accuracy in delivering drugs that far surpasses present
methods. Typically over 90% of a drug is wasted in the body, which leads to
unwanted side effects. Modern chemotherapy bombards patients with drugs in
the hope that tumorous cells will be destroyed. The lack of specificity of
current drug delivery techniques mean patients' healthy cells are destroyed
indiscriminately along with cancer cells.
Using nanotechnology to combat cancer is not new. Abraxane, the first
nanoparticulate drug delivery product for the treatment of breast cancer,
launched six years ago. There are now hundreds of new nanotech-based
treatments under development, ranging from reformulation of existing drugs to
enhance their efficacy to radical new "magic bullet" therapies.
The healthcare market is changing. We are seeing a paradigm shift away from
blockbusters and a 'one-size fits all' approach to a more personalised
medicine based on an individual's unique genome and immune response. The more
scientists learn about the molecular causes for disease the more targeted and
effective nanotechnology-enabled drug delivery therapies will become.
Table of Contents
Table of Contents
TABLE OF EXHIBITS
EXECUTIVE SUMMARY
CHAPTER 1 - INTRODUCTION
REPORT SCOPE
METHODOLOGY
Procurement
Calculation of CAGR
THE NANOSCALE
Two biological examples that illustrate nanoscale:
CHAPTER 2 - NANOTECHNOLOGY IN MEDICINE AND BIOMEDICINE
OVERVIEW OF NANOTECHNOLOGY IN MEDICINE AND BIOMEDICINE
Why is Nanotechnology A Critical Application for Medicine and
Biomedicine?
Why Nanotechnology Is Needed for Medicine and Biomedicine
WHAT ARE THE KEY DRIVERS FOR ADOPTION OF NANOTECHNOLOGY IN MEDICINE AND
BIOMEDICINE?
The Aim Of Drug Targeting
Rapid Market Growth
Market Drivers For Enhanced Drug Delivery
Increasing Proportion of The Ageing Population
Demand For More Affordable Health Care
Public Health - Ending disease
Demand for More Innovation
Social responsibility
THE KEY APPLICATIONS OF NANOTECHNOLOGY IN MEDICINE AND BIOMEDICINE
How Nanotechnology Can Benefit Drug Delivery
Nanotechnology in Medical and Biomedical Diagnostics
Nanotechnology in Regenerative Medicine and Tissue Engineering
Other Applications For Nanomaterials In The Medical And Pharmaceutical
Sector
PROMISING EXAMPLES OF NANOTECHNOLOGY ENABLED DRUG DELIVERY
Case Study 1 - Magnetic Field Acts as "Remote Control" to Deliver
Nanomedicine
Case Study 2 - Adaptive Micro and Nanoparticles: Temporal Control Over
Carrier Properties to Facilitate Drug Delivery
Case Study 3 - Fabrication of a Nanocarrier System Through Self-Assembly
of Plasma Protein And Its Tumour Targeting
Case Study 4 - IBM And The Institute of Bioengineering And
Nanotechnology Find Breakthrough For MRSA
CHAPTER 3 - RISK & REGULATION 43
THREE KEY BARRIERS TO THE ADOPTION OF NANOTECHNOLOGY IN MEDICINE AND
BIOMEDICINE
Nanotoxicity Nanopollution and Nanosafety
Ethical Considerations Of Nanotherapies
Delayed Nanoregulation
FIVE CURRENT & FUTURE CHALLENGES IN THE ADOPTION OF NANOTECHNOLOGY IN
MEDICINE AND BIOMEDICINE
Current & Future Challenges of Nanosafety And Risk Management
Current & Future Challenges of Nanoregulation
Current & Future Challenges for the Nanomedicine Industry
Current & Future Challenges of Sustained Innovation
Current & Future Challenges of Cooperation
CHAPTER 4 - MARKET FOR NANOCARRIERS
GLOBAL MARKET ANALYSIS: 2000-2010 (WITHOUT SEGMENTATION)
GLOBAL MARKET FORECAST: 2011-2021 (WITHOUT SEGMENTATION)
DISCUSSION OF NANOPARTICLES & NANOCARRIERS
Overview of The Key Nanotechnologies Used in Drug Delivery Sorted by
Applications
Nanopharmaceuticals
Nanotechnology In Drug Delivery
Nanobiotechnology In Drug Delivery
Analytical Techniques For Nanoparticle Drug Delivery
Properties
Production of Nanoparticles
Measuring Dispersion of Nanoparticles
Characterisation of Carrier Systems
Nanocarriers
Classification of Nanocarriers
Multifunctional Nanocarriers - Drug Delivery And Medical / Biomedical
Diagnostics
The Most Relevant Technologies in The Key Area of Nanotechnology in Drug
Delivery
Stage of Development of Key Nanotechnologies Used in Drug Delivery
Clinically Approved Nanocarrier-Based Drug Formulations With Presence on
The Market
The First Nanoparticle Drug Delivery System Reaches The Market 81
Present And Future Applications
TECHNOLOGY ADOPTION ROADMAP
Projected Product Pipeline For Nanocarrier-Based Drug Formulations In
Drug Delivery Market
Available Applications Of Nanoparticles In Drug Delivery
Semapimod®(cytokine, pharmasciences)
Paxceed™
Theralux™
NucrystR
iSPERSE™
ANALYSIS OF TAM FOR NANOCARRIERS: 2000-2010
TAM FORECAST FOR NANOCARRIERS: 2011-2021
APPENDIX
PUBLISHING ACTIVITY BY ORGANIZATION (2000-2010)
Table of Exhibits
Exhibit 1.1
Formula for the calculation of the Compound Annual Growth Rate (CAGR),
(top).
Formula for the calculation of the Compound Annual Growth Rate (CAGR) in
this report, for the 2011-2021 period, (bottom) [2].
Exhibit 1.2
Formula for the verification of the calculated values of the Compound
Annual Growth Rate (CAGR), (top).
Formula for the verification of the calculated values of the Compound
Annual Growth Rate (CAGR) in this report, for the 2011-2021 period, (bottom)
[2].
Exhibit 1.3
Nanometers in a meter (top). Meters in a nanometer (bottom).
Exhibit 2.1
Illustration of the fact that the periodic table of elements, as we know
it (at meter scale) governed by classic Newtonian laws of physics. However,
when perceived at nanoscale, those elements are governed by the laws of
quantum physics.
Exhibit 2.2
Proportion of the population aged over 65 and over 80 [7].
Exhibit 2.3
Illustration of a diagram of each property of nanocarriers (size, shape,
surface chemistry and mechanical properties) and their parameters subjected to
optimization in order to improve their efficiency [10].
Exhibit 3.1
Specified expected barriers in the development of particular types of
nanoparticles (Courtesy of CienNanoroadmap Synthesis Report), [6].
Exhibit 3.2
Illustration of the measures adoption roadmap to combat/attenuate the key
barriers to the adoption of nanotechnology in medicine and biomedicine
(Source: Cientifica, Ltd.).
Exhibit 3.3
Table representing the Total Addressable Market, TAM (2000-2010), for
nanotechnology in drug delivery, without segmentation, source: Cientifica (all
figures US$ Million Dollars).
Exhibit 3.4
Line chart representing Total Addressable Market, TAM (2000-2010), for
nanotechnology in drug delivery, without segmentation, source: Cientifica (all
figures US$ Million Dollars).
Exhibit 3.5
Bar chart representing Total Addressable Market, TAM (2000-2010), for
nanotechnology in drug delivery, without segmentation, source: Cientifica (all
figures US$ Million Dollars).
Exhibit 3.6
Table representing the Total Addressable Market, TAM forecast by 2021 (for
the 2011-2021 period), for nanotechnology in drug delivery, without
segmentation, source: Cientifica (all figures US$ Million Dollars).
Exhibit 3.7
Line chart representing the Total Addressable Market, TAM forecast by 2021
(for the 2011-2021 period), for nanotechnology in drug delivery, without
segmentation, source: Cientifica (all figures US$ Million Dollars).
Exhibit 3.8
Bar chart representing the Total Addressable Market, TAM forecast by 2021
(for the 2011-2021 period), for nanotechnology in drug delivery, without
segmentation, source: Cientifica (all figures US$ Million Dollars).
Exhibit 4.1
Typical Image of Colloidal Gold Nanoparticles [1].
Exhibit 4.2
Examples of nanocarriers used for targeting cancer. (A) A whole range of
delivery agents are possible but the main components typically include a
nanocarrier, a targeting moiety conjugated to the nanocarrier and a cargo
(such as the desired chemotherapeutic drugs); (B) Schematic diagram of the
drug conjugation and entrapment processes. The chemotherapeutics could be
bound to the nanocarrier, as in the use of polymer - drug conjugates,
dendrimers and some particulate carriers or they could be entrapped inside the
nanocarrier [3].
Exhibit 4.3
Schematic representation of different mechanisms of drug delivery to
tumours using nanocarriers. Polymeric nanoparticles are shown as
representative nanocarriers (circles). Passive tissue targeting is achieved by
extravasation of nanoparticles through increased permeability of the tumour
vasculature and ineffective lymphatic drainage (EPR effect). Active cellular
targeting (inset) can be achieved by functionalizing the surface of
nanocarriers with ligands that induce cell-specific recognition and binding.
The nanocarriers can (a) release their contents in close proximity to the
target tumour cells; (b) attach to the membrane of the tumour cell and play
the role of an extracellular sustained-release drug depot; or (c) internalize
into the tumour cell [3].
Exhibit 4.5
Representative examples of clinically approved nanocarrier-based drug
formulations with presence on the market [4].
Exhibit 4.6
Some examples of nano-based platforms and their current stage of
development for use in cancer therapy [3].
Exhibit 4.26
Table representing the Total Addressable Market, TAM (2000-2010), for
nanotechnology in drug delivery, all most relevant key technologies, source:
Cientifica (all figures US$ Million Dollars).
Exhibit 4.27
3-D pie chart representing the Total Addressable Market, TAM in 2010, for
nanotechnology in drug delivery, all key technologies studied, source:
Cientifica (all figures in percentage).
Exhibit 4.28
Horizontal bar graph representing the Total Addressable Market, TAM in
2010, for nanotechnology in drug delivery, all key technologies studied,
source: Cientifica (all figures US$ Million Dollars).
Exhibit 4.29
Line chart representing the Total Addressable Market, TAM (2000-2010), for
nanotechnology in drug delivery, all key technologies studied, source:
Cientifica (all figures US$ Million Dollars).
Exhibit 4.30
3-D stacked vertical bar graph representing the Total Addressable Market,
TAM (2000-2010) , for nanotechnology in drug delivery, all key technologies
studied, source: Cientifica (all figures US$ Million Dollars).
Exhibit 4.31
3-D stacked area chart representing the Total Addressable Market, TAM
(2000-2010) , for nanotechnology in drug delivery, all key technologies
studied, source: Cientifica (all figures US$ Million Dollars).
Exhibit 4.32
3-D pie chart representing the Total Addressable Market, TAM in 2010, for
nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica
(all figures in percentage).
Exhibit 4.33
Horizontal bar graph representing the Total Addressable Market, TAM in
2010, for nanotechnology in drug delivery, nanocarriers as a whole, source:
Cientifica (all figures US$ Million Dollars).
Exhibit 4.34
Line chart representing the Total Addressable Market, TAM (2000-2010), for
nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica
(all figures US$ Million Dollars).
Exhibit 4.35
3-D stacked vertical bar graph representing the Total Addressable Market,
TAM (2000-2010) , for nanotechnology in drug delivery, nanocarriers as a
whole, source: Cientifica (all figures US$ Million Dollars).
Exhibit 4.36
3-D stacked area chart representing the Total Addressable Market, TAM
(2000-2010) , for nanotechnology in drug delivery, nanocarriers as a whole,
source: Cientifica (all figures US$ Million Dollars).
Exhibit 4.45
In vivo effects of nanocrystals-based drug formulations [6].
Exhibit 4.67
Table representing the Total Addressable Market, TAM forecast by 2021 (for
the 2011-2021 period), for nanotechnology in drug delivery, all key
technologies, source: Cientifica (all figures US$ Million Dollars).
Exhibit 4.68
3-D pie chart representing the Total Addressable Market, TAM forecast in
2021, for nanotechnology in drug delivery, all key technologies studied,
source: Cientifica (all figures in percentage).
Exhibit 4.69
Horizontal bar graph representing the Total Addressable Market, TAM
forecast in 2021, for nanotechnology in drug delivery, all key technologies
studied, source: Cientifica (all figures in percentage).
Exhibit 4.70
Line chart representing the Total Addressable Market, TAM forecast by 2021
(for the 2011-2021 period), for nanotechnology in drug delivery, all key
technologies studied, source: Cientifica (all figures US$ Million Dollars).
Exhibit 4.71
3-D stacked vertical bar graph representing the Total Addressable Market,
TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug
delivery, all key technologies studied, source: Cientifica (all figures US$
Million Dollars).
Exhibit 4.72
3-D stacked area chart representing the Total Addressable Market, TAM
forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug
delivery, all key technologies studied, source: Cientifica (all figures US$
Million Dollars).
Exhibit 4.73
3-D pie chart representing the Total Addressable Market, TAM forecast in
2021, for nanotechnology in drug delivery, nanocarriers as a whole, source:
Cientifica (all figures in percentage).
Exhibit 4.74
Horizontal bar graph representing the Total Addressable Market, TAM
forecast in 2021, for nanotechnology in drug delivery, nanocarriers as a
whole, source: Cientifica (all figures US$ Million Dollars).
Exhibit 4.75
Line chart representing the Total Addressable Market, TAM forecast by 2021
(for the 2011-2021 period), for nanotechnology in drug delivery, nanocarriers
as a whole, source: Cientifica (all figures US$ Million Dollars).
Exhibit 4.76
3-D stacked vertical bar graph representing the Total Addressable Market,
TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug
delivery, nanocarriers as a whole, source: Cientifica (all figures US$ Million
Dollars).
Exhibit 4.77
3-D stacked area chart representing the Total Addressable Market, TAM
forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug
delivery, nanocarriers as a whole, source: Cientifica (all figures US$ Million
Dollars).
Exhibit 4.78
3-D pie chart representing the Total Addressable Market, TAM forecast in
2021, for nanotechnology in drug delivery, nanocarriers versus drug
nanocrystals, source: Cientifica (all figures in percentage).
Appendix
Exhibit A.1
Table of the top 20 organizations showing the highest publishing activity
in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug
Delivery. World Region: North America; country: USA.
Organizations are ordered first by descending order of total articles
published and then ordered alphabetically (increasing order), if applicable.
Exhibit A.2
Table of the top 20 organizations showing the highest publishing activity
in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug
Delivery. World Region: European Union; country: Germany.
Organizations are ordered first by descending order of total articles
published and then ordered alphabetically (increasing order), if applicable.
Exhibit A.3
Table of the top 20 organizations showing the highest publishing activity
in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug
Delivery. World Region: European Union; country: France.
Organizations are ordered first by descending order of total articles
published and then ordered alphabetically (increasing order), if applicable.
Exhibit A.4
Table of the top 20 organizations showing the highest publishing activity
in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug
Delivery. World Region: European Union; country: UK.
Organizations are ordered first by descending order of total articles
published and then ordered alphabetically (increasing order), if applicable.
Exhibit A.5
Table of publishing activity in PubMed periodicals (2000-2010), based on
PubMed, for Nanotechnology in Drug Delivery. Country: Russian Federation.
Organizations are ordered alphabetically (increasing order).
Exhibit A.6
Table of the top 20 organizations showing the highest publishing activity
in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug
Delivery. World Region: Asia; country: India.
Organizations are ordered first by descending order of total articles
published and then ordered alphabetically (increasing order), if applicable.
Exhibit A.7
Table of the top 20 organizations showing the highest publishing activity
in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug
Delivery. World Region: Asia; country: India.
Organizations are ordered first by descending order of total articles
published and then ordered alphabetically increasing order), if applicable.
Exhibit A.8
Table of the top 20 organizations showing the highest publishing activity
in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug
Delivery. World Region: Asia; country: Japan.
Organizations are ordered first by descending order of total articles
published and then ordered alphabetically (increasing order), if applicable.
Exhibit A.9
Table of the top 20 organizations showing the highest publishing activity
in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug
Delivery. World Region: Asia; country: P R China.
Organizations are ordered first by descending order of total articles
published and then ordered alphabetically (increasing order), if applicable.
Exhibit A.10
Table of the top 20 organizations showing the highest publishing activity
in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug
Delivery. World Region: Asia; country: South Korea (Republic of Korea).
Organizations are ordered first by descending order of total articles
published and then ordered alphabetically (increasing order), if applicable.
Exhibit A.11
Table of publishing activity in PubMed periodicals (2000-2010), based on
PubMed, for Nanotechnology in Drug Delivery. Asia; country: Taiwan.
Organizations are ordered first by descending order of total articles
published and then ordered alphabetically (increasing order), if applicable.
Nanotechnology for Drug Delivery: Global Market for Nanocarriers published by Cientifica Ltd in February 7, 2012. This report consists of 108 Pages and the price starts from US $ 1599.
Press Release
Nanocarriers to Account for 40% of Nanotechnology for Drug Delivery (NDD) Market by 2021
February 20th, 2012
Global Information Inc. would like to present a new market research report, "Nanotechnology for Drug Delivery: Global Market for Nanocarriers" by Cientifica Ltd.
"We forecast the total market size in 2021 to be US$136 billion, with a 60/40 split between nanocrystals and nanocarriers respectively, although developing new targeted delivery mechanisms may allow more value to be created for companies and entrepreneurs," said Tim Harper, CEO of Cientifica Ltd.
Drugs are loaded into nanocarriers (also called nanoshells or nanoparticles, between 1 and 100 nm), then transported through the body to the target site. This kind of targeted drug delivery for the treatment of cancers is one of the most anticipated and discussed benefits of nanotechnology-enabled medicine as it offers a level of accuracy in delivering drugs that far surpasses present methods. Typically over 90% of a drug is wasted in the body, which leads to unwanted side effects. Modern chemotherapy bombards patients with drugs in the hope that tumorous cells will be destroyed. The lack of specificity of current drug delivery techniques mean patients healthy cells are destroyed indiscriminately along with cancer cells.
"Its the equivalent of using a nuclear bomb to eliminate just a handful of enemies," said Harper. "In theory, as long as the nanocarrier is designed specifically enough, it should be possible to deliver all of the drug to the target site whilst leaving healthy cells unaffected. This greatly reduces treatment time, costs and unwanted side effects."
Using nanotechnology to combat cancer is not new. Abraxane, the first nanoparticulate drug delivery product for the treatment of breast cancer, launched six years ago. There are now hundreds of new nanotech-based treatments under development, ranging from reformulation of existing drugs to enhance their efficacy to radical new "magic bullet" therapies.
"The healthcare market is changing. We are seeing a paradigm shift away from blockbusters and a one-size fits all approach to a more personalized medicine based on an individuals unique genome and immune response. The more scientists learn about the molecular causes for disease the more targeted and effective nanotechnology-enabled drug delivery therapies will become," said Harper.
